Article
Targeting public neoantigens for cancer immunotherapy.
Nature cancer - 1 May 2021
Pearlman Alexander H, Hwang Michael S, Konig Maximilian F, Hsiue Emily Han-Chung, Douglass Jacqueline, DiNapoli Sarah R, Mog Brian J, Bettegowda Chetan, Pardoll Drew M, Gabelli Sandra B, Papadopoulos Nicholas, Kinzler Kenneth W, Vogelstein Bert, Zhou Shibin
Abstract excerpt
Several current immunotherapy approaches target private neoantigens derived from mutations that are unique to individual patients' tumors. However, immunotherapeutic agents can also be developed against public neoantigens derived from recurrent mutations in cancer driver genes. The latter approaches target proteins that are indispensable for tumor growth, and each therapeutic agent can be applied to numerous...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.